Prime Medicine, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Prime Medicine, Inc. (PRME) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $93.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2026-08-06
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-06-30 was $43.06M, a 282.80% increase year-over-year.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-03-31 was $50.89M, a 1596.27% increase year-over-year.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-12-31 was $39.10M, a 18.84% increase year-over-year.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-09-30 was $42.43M, a 30.78% decline year-over-year.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2025 was $95.78M, a 53.09% decline from fiscal 2024.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2024 was $204.20M, a 54.05% increase from fiscal 2023.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $132.56M, a 42.53% increase from fiscal 2022.
- Prime Medicine, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $93.00M, a 615.38% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $93.95M 10-Q · filed 2026-08-06 | $133.05M derived: sum of 3 quarters · filed 2026-08-06 | $175.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $50.89M 10-Q · filed 2026-05-07 | $89.99M derived: sum of 2 quarters · filed 2026-05-07 | $132.42M derived: sum of 3 quarters · filed 2026-05-07 | $143.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $39.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $81.53M derived: sum of 2 quarters · filed 2026-03-03 | $92.78M derived: sum of 3 quarters · filed 2026-08-06 | $95.78M 10-K · filed 2026-03-03 |
| 2025-09-30 | $42.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $53.68M derived: sum of 2 quarters · filed 2026-08-06 | $56.68M 10-Q · filed 2025-11-07 | $89.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.25M 10-Q · filed 2026-08-06 | $47.15M derived: sum of 3 quarters · filed 2026-08-06 | $108.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-07 | $35.90M derived: sum of 2 quarters · filed 2026-05-07 | $97.20M derived: sum of 3 quarters · filed 2026-05-07 | $134.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $32.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $94.20M derived: sum of 2 quarters · filed 2026-03-03 | $131.70M derived: sum of 3 quarters · filed 2026-03-03 | $204.20M 10-K · filed 2026-03-03 |
| 2024-09-30 | $61.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $98.80M derived: sum of 2 quarters · filed 2025-11-07 | $171.30M 10-Q · filed 2025-11-07 | $218.84M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $37.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $110.00M 10-Q · filed 2025-08-07 | $157.53M derived: sum of 3 quarters · filed 2025-08-07 | $177.56M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $72.50M 10-Q · filed 2025-05-08 | $120.03M derived: sum of 2 quarters · filed 2025-05-08 | $140.06M derived: sum of 3 quarters · filed 2025-05-08 | $170.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $47.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $67.56M derived: sum of 2 quarters · filed 2025-02-28 | $97.56M derived: sum of 3 quarters · filed 2025-02-28 | $132.56M 10-K · filed 2025-02-28 |
| 2023-09-30 | $20.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $50.02M derived: sum of 2 quarters · filed 2024-11-12 | $85.02M 10-Q · filed 2024-11-12 | $110.02M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $65.00M 10-Q · filed 2024-08-08 | $90.00M derived: sum of 3 quarters · filed 2024-08-08 | $96.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $35.00M 10-Q · filed 2024-05-10 | $60.00M derived: sum of 2 quarters · filed 2024-05-10 | $66.00M derived: sum of 3 quarters · filed 2024-05-10 | $95.50M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $31.00M derived: sum of 2 quarters · filed 2024-03-01 | $60.50M derived: sum of 3 quarters · filed 2024-03-01 | $93.00M 10-K · filed 2024-03-01 |
| 2022-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $35.50M derived: sum of 2 quarters · filed 2023-11-03 | $68.00M 10-Q · filed 2023-11-03 | $81.00M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $29.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $62.00M 10-Q · filed 2023-08-07 | $75.00M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $32.50M 10-Q · filed 2023-05-11 | $45.50M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $13.00M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |